|View printer-friendly version|
|StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration|
ARM's 4th Annual State of the Industry Briefing is a top-level gathering of key stakeholders including business executives, investors, patient advocates and academic leaders, who will learn about the most recent advances in regenerative medicine and the outlook for the industry in the coming year. Top executives, chief medical officers and principal investigators will cover Phase II and Phase III trials that are expected to yield significant data or be completed in 2014, with a discussion of the expected clinical endpoints. In addition, the program will highlight the most impactful recent financings in the Regenerative Medicine industry including IPOs, reverse mergers and follow-on offerings, through a high-level discussion of what all of this activity means for the sector's progress and fundraising opportunities over the next 12-18 months.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, the prospect for screening and then enrolling additional patients with incomplete spinal cord injury; the prospect for evaluating trial patients for changes in their sensation, motor function and bowel/bladder function; the potential of the Company's HuCNS-SC cells to treat spinal cord injury and other central nervous system diseases and disorders; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury or in future clinical trials of proposed therapies for other diseases or conditions; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended